FAFnu Anchal

Fnu Anchal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fnu Anchal has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mortality attributed to complications of surgical operations in the United States: a retrospective cohort study of death certificate data, 1999–2024

    by Dheeraj Kumar Alias Sailish, Pranjal Wadhwani, Jagdesh Kumar, Sagar Kumar, Iqra Javed, Fnu Anchal, Mohit Kumar, Fnu Chandni, Fnu Pritee, Sakshi Kukreja, et al.

    Background: Complications of surgical operations remain an important contributor to preventable mortality, despite advances in perioperative care, anesthesia, and surgical safety. However, long-term national mortality trends and demographic disparities associated with surgical complications remain poorly characterized at the population level. Methods: We conducted a retrospective analysis of U.S. mortality data from the CDC WONDER Multiple Cause of Death database between 1999 and 2024. Deaths attributed to complications of surgical operations were identified using ICD-10 Y83 codes. Age-adjusted mortality rates (AAMRs) per 100 000 population were calculated using the 2000 U.S. standard population. Temporal trends were evaluated using Joinpoint regression analysis to estimate annual percentage changes (APCs) with 95% confidence intervals (CIs). Mortality patterns were stratified by sex, race/ethnicity, census region, urbanization status, and state. Results: A total of 470 098 deaths were attributed to complications of surgical operations during the study period. The overall AAMR was 5.3 (95% CI: 5.2–5.4). Mortality declined significantly from 8.1 in 1999 to 3.4 in 2015 (APC: −5.56, P < 0.000001), increased sharply to 7.9 in 2021 (APC: 16.20, P < 0.000001), and subsequently declined to 3.2 in 2024 (APC: −31.85, P < 0.000001). Men demonstrated consistently higher mortality than women (6.7 vs. 4.3 per 100 000). Non-Hispanic Black and American Indian/Alaska Native populations had the highest mortality rates, whereas Asian or Pacific Islander populations had the lowest. Mortality was higher in non-metropolitan areas and in several Southern and Midwestern states. Conclusion: Mortality associated with complications of surgical operations in the United States has demonstrated substantial temporal variation and persistent demographic and geographic disparities between 1999 and 2024. Further studies using patient-level clinical datasets are needed to clarify the underlying contributors to these patterns and identify potential targets for intervention.

  • Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-analysis

    by Saad Ashraf, Shariq A. Wani, Muhammad Burhan, Muhammad A. Naveed, Fnu Anchal, Hamza Irfan, Bazil Azeem, Ahila Ali

    Uncontrolled hypertension remains a major global health concern and a leading cause of cardiovascular morbidity and mortality. Aldosterone dysregulation plays a critical role in resistant hypertension, and lorundrostat, a novel aldosterone synthase inhibitor, offers a promising therapeutic approach by directly inhibiting aldosterone production. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of lorundrostat in adults with uncontrolled hypertension. Comprehensive searches of MEDLINE (PubMed), ScienceDirect, Google Scholar, and Cochrane databases were conducted up to July 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with the protocol registered on PROSPERO (CRD420251091117). Three randomized controlled trials involving 1568 participants (1165 lorundrostat and 403 placebo) were included, all demonstrating low risk of bias. Pooled analysis revealed that lorundrostat significantly reduced systolic blood pressure (BP) (−8.50 mm Hg, 95% confidence interval: –11.63 to −5.36, P < 0.00001) and diastolic BP (−3.53 mm Hg, 95% confidence interval: –5.61 to −1.45, P = 0.0009) compared with placebo, with no heterogeneity observed. However, lorundrostat was associated with higher risks of hyperkalemia (RR = 5.84, P = 0.01), symptomatic hypotension (RR = 2.98, P = 0.03), serious adverse events (RR = 3.31, P = 0.03), and hyponatremia (RR = 2.03, P = 0.01), although there were no significant differences in moderate or severe adverse events or reduction in kidney function. Publication bias was noted for diastolic BP and selected safety outcomes. In conclusion, lorundrostat demonstrates clinically meaningful BP reduction in uncontrolled hypertension compared with placebo, but with an increased risk of electrolyte disturbances and hypotension. Cautious use and close monitoring are warranted, and larger, long-term trials are needed to further define its safety and therapeutic role.


  • Open Access

    Hypertensive kidney disease with concurrent diabetes mellitus: national mortality trends from CDC WONDER 1999–2024

    by Areeba Pervaiz, Jamil Ahmed Jamali, Muhammad Mohsin Zahoor, Muhamma Saqib Usman, Kashish Devi, Mamita Kumar, Fnu Simran, Zulfiqar Ali, Noor Muhammad, Rahul Raja, et al.

    Background: Hypertension and diabetes are among the most prevalent conditions in the world, which can severely affect the kidneys, especially when they occur together. This study analyzes mortality trends among the American population with hypertensive kidney disease (HKD) and diabetes. Methods: We carried out a retrospective analysis from 1999 to 2024 of nationwide mortality data obtained from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. We included individuals with HKD diabetes (ICD-10 codes: I12, E10-E14) using a multiple cause of death approach (reporting any mention of the diagnosis as an underlying or contributing cause of death). We calculated the age-adjusted mortality rates (AAMR) per 100 000 population, and analysis based on year, gender, race/ethnicity, state, and urban/rural classification was performed. Joinpoint regression analysis was used to determine significant annual percent changes (APCs) in AAMR over the study period. Results: A total of 242 071 deaths among the patient population were reported, and analysis revealed a significant increase in the overall AAMR for mortality related to HKD and diabetes, rising from 1.1 per 100 000 in 1999 to 4.9 per 100 000 in 2024. Men consistently showed higher AAMRs (overall 2.4) compared to women (overall 2.0). Among racial and ethnic groups, the highest overall AAMR was observed in the non-Hispanic Black or African American population (6.9). States that showed the highest AAMR included California, South Carolina, Texas, Mississippi, and the District of Columbia. Additionally, nonmetropolitan areas demonstrated a generally higher AAMR (2.6) compared to metropolitan areas (2.5). Conclusions: HKD-related mortality among diabetic Americans surged between 1999 and 2024, with gender, race/ethnicity, and geographic location disparities, especially in nonmetropolitan areas. Targeted health strategies and interventions are vital to reducing mortality and addressing these disparities.